Background: Precise delineation of non-contrast-enhancing tumor (nCET) in glioblastoma (GB) is critical for maximal safe resection, yet routine imaging cannot reliably separate infiltrative tumor from vasogenic edema. The aim of this study was to develop and validate an automated method to identify peritumoral subregions compatible with nCET and assess its prognostic value. Methods: Pre-operative T2-weighted and FLAIR MRI from 940 patients with newly diagnosed GB in four multicenter cohorts were analyzed. A deep-learning model segmented enhancing tumor, edema and necrosis; a non-local, spatially varying finite mixture model was applied to identify edema subregions characterized by relatively lower FLAIR hyperintensity, hypothesized to reflect nCET-related tissue. The ratio of these subregions to total edema volume defined the T2/FLAIR Heterogeneity Index (TFHI). Associations between TFHI and overall survival (OS) were examined with Kaplan–Meier curves and multivariable Cox regression. Results: Higher TFHI values stratified patients with shorter OS. In the NCT03439332, TFHI above the optimal threshold was associated with a twofold increased hazard of death (hazard ratio [HR] 2.07, 95 % confidence interval 1.33-3.21; P = .0013) and a reduction in median survival of 98 days. Significant, though smaller, prognostic effects were confirmed in GLIOCAT & BraTS (HR= 1.37; P = .047), OUS (HR = 1.37; P = .0032) and pooled analysis (HR= 1.26; P = .0008). TFHI remained an independent predictor after adjustment for age, extent of resection and MGMT methylation. Conclusions: We present a reproducible, server-hosted tool for automated identification of imaging-defined, putative nCET-related peritumoral subregions and TFHI biomarker extraction that enables independent prognostic stratification. This approach provides a quantitative framework for studying peritumoral heterogeneity in GB.
Background: Stereotactic radiosurgery (SRS) is an established treatment option for medically refractory trigeminal neuralgia (TN). However, clinical evidence regarding dedicated gyroscopic radiosurgery systems remains limited. This study aimed to evaluate the efficacy, latency of response, safety, retreatment rate, and potential clinical and dosimetric predictors of outcome following ZAP-X gyroscopic radiosurgery for TN. Methods: A consecutive series of patients with pharmacologically refractory TN treated with ZAP-X gyroscopic radiosurgery between February 2023 and September 2025 was analyzed. Treatment consisted of a single isocenter targeting approximately 5 mm of the cisternal-retrogasserian trigeminal nerve, with a maximum dose of 90 Gy and a V70 Gy coverage objective ≥ 50%, using 4 or 5 mm collimators. Pain outcome was assessed using the Barrow Neurological Institute Pain Intensity Scale (BNI), and sensory toxicity was evaluated using the BNI Facial Numbness Scale. Clinical and treatment-related predictors of failure and retreatment were explored using binary logistic regression. Results: Following radiosurgery, 87.5% of patients achieved satisfactory pain control (BNI I–IIIb; 95% CI, 78.8–96.2%), with a significant overall improvement in BNI score compared with baseline (p < 0.001) at the 12 months of follow-up. Half of the patients experienced clinical improvement within the first 15 days. Treatment-related toxicity occurred in 8.9% of patients, while 26.8% required repeat radiosurgery during follow-up. The decision to perform retreatment is made when the patient has shown no improvement in the BNI score at 6 months after the initial treatment. Baseline BNI grade V was the only statistically significant predictor of treatment failure, conferring a more than ninefold higher odds of non-response compared with BNI grade IV (OR 9.33; 95% CI, 1.66–52.3; p = 0.011). Female sex showed a nonsignificant trend toward a lower risk of failure (OR 0.65; 95% CI, 0.13–3.24; p = 0.596). Neither multiple sclerosis-associated TN nor other etiological or dosimetric variables significantly predicted treatment failure. A greater number of beams showed a trend toward an increased probability of retreatment (OR 1.01; p = 0.091), although statistical significance was not reached. Conclusions: Gyroscopic radiosurgery with ZAP-X provides high rates of pain control, rapid clinical response, and a favorable safety profile in patients with refractory TN. Greater baseline pain severity appears to be associated with poorer treatment response. These findings support ZAP-X as an effective frameless radiosurgical alternative for TN, although larger prospective studies are required to identify robust clinical, dosimetric, and radiobiological predictors of long-term outcome.